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Abstract
Introduction: Leprosy exhibits a wide spectrum of presentation, varying from the tuberculoid to
the lepromatous pole, with immunologically unstable borderline forms in-between, depending upon
the immune status of the individual. The clinical system of classification for the purpose of
treatment includes the number of skin lesions and nerves involved as the basis for classifying the
patients into multibacillary and paucibacillary.
Case presentation: A 20-year-old man belonging to a moderately endemic leprosy area in the
Terai region of Nepal reported a large single, hypopigmented, well defined anaesthetic lesion on
his left thigh extending to his knee which had been present for 2 years. There was no other nerve
involvement. Clinical diagnosis was tuberculoid leprosy and immunological lateral flow test for anti-
Phenolic glycolipid-I antibody was positive. Six months of paucibacillary multidrug treatment was
advised immediately. However, the patient was reclassified as multibacillary on the basis of a
positive skin smear and appropriate treatment of 24 months multibacillary multidrug regimen was
commenced after only 1 week. Slit skin smear examination for Mycobacterium leprae from the lesion
revealed a bacterial index of 4+ while it was negative from the routine sites. Histopathological
examination from skin biopsy of the lesion further supported the bacterial index of the lesion
granuloma which was 2+ and the patient was diagnosed as borderline tuberculoid. Bacteriological,
histological, and immunological findings of this patient were borderline tuberculoid leprosy and he
should have been treated with multibacillary regimen from the beginning. Five months after
commencement of treatment, the patient developed a leprae reaction of Type 1 or reversal
reaction with some nerve function impairment and enlargement of the lateral popliteal nerve of the
left leg. This reversal reaction was managed by standard oral prednisolone whilst continuing the
multibacillary multidrug regimen.
Conclusion: This case illustrates and emphasizes the importance of slit-skin smear and biopsy as
routine in all new cases to help differentiate multibacillary from paucibacillary for correct
treatment. It further suggests that there are factors yet undetermined which play a significant role
in determining the host response to M. leprae which is a remaining challenge in this disease.
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Introduction
Leprosy is a chronic infectious disease caused by Mycobac-
terium leprae and is an ancient scourge that still affects ≥ 4
persons per 10,000 in Brazil, India, Madagascar, Mozam-
bique and Nepal. Globally, Nepal is among the six major
endemic countries which account for 23% of all new cases
detected during 2005 and 24% of registered cases at the
beginning of 2006 [1,2]. Leprosy exhibits a wide spectrum
of presentation, varying from the tuberculoid to the lepro-
matous pole, with the immunologically unstable border-
line forms in-between, depending upon the immune
status of the individual. At the lepromatous pole, the
patients lack effective cell-mediated immunity to M. leprae
and bacilli proliferate, while at the tuberculoid pole, the
patients have cell mediated immunity towards M. leprae
and there is elimination of mycobacteria.
Case presentation
A 20-year-old man belonging to a moderately endemic
leprosy area in the Terai region of Nepal presented in our
clinic as a referred patient from a teaching hospital with
the history of 2 years. On clinical examination, a solitary
hypopigmented, anaesthetic lesion was present on his left
thigh extending to his knee. The surface of the lesion was
dry and it had a length of approximately 15 cm with raised
edge as shown in Figure 1. No other lesions were noted
over the entire body. There was no peripheral nerve thick-
ening. No history of contact with leprosy could be elicited.
Furthermore, the rapid lateral flow test (supplied by Linda
Oskam, KIT Biomedical Research, The Netherlands and
Ray Cho, Yonsei University, Korea) for anti-Phenolic gly-
colipid-I (PGL-I) antibody of M. leprae was positive. Blood
count was normal and the standard nerve function meas-
urements by voluntary muscle testing and sensory test
(VMT/ST) of the hand and feet were within normal limits.
His slit skin smear and biopsy were sent for laboratory
investigations.
His clinical presentation was consistent with tuberculoid
leprosy (TT) and paucibacillary (PB) multidrug treatment
(MDT) was initiated immediately comprising 600 mg of
Rifampicin once a month and 100 mg of Dapsone daily.
The patient was under PB MDT for a week; however, once
the slit skin smear report was obtained, this prompted the
clinician to change treatment from 6 months PB to 24
months multibacillary (MB) MDT regimen comprising
Rifampicin 600 mg once a month, Clofazimine 300 mg
once a month followed by 50 mg daily and Dapsone 100
mg daily.
Slit skin smear examination for M. leprae from the lesion
revealed a Bacterial Index (BI) of 4+ (10–100 acid fast
bacilli per oil immersion microscopic field on Ridley's
logarithmic scale) as shown in Figure 2 while it was nega-
tive from the routine sites of the ear lobes, thigh and arm.
The Morphological Index was 0%. On histopathological
examination, the biopsy from the lesion revealed skin and
subcutaneous tissue. There was an epidermal atrophy
with mild orthokeratosis. Small aggregates of histocytes
and lymphocytes were seen around vessels and skin adn-
Initial solitary lesion plaque after 5 months of multibacillary  multidrug treatment Figure 1
Initial solitary lesion plaque after 5 months of multi-
bacillary multidrug treatment. Reversal reaction: 5 
months after initial presentation and commencement of 
multibacillary multidrug treatment.
Microscopic observation of acid fast bacilli (red rods) in the  slit skin smear fluid from the solitary lesion in the initial pres- entation of the patient Figure 2
Microscopic observation of acid fast bacilli (red rods) 
in the slit skin smear fluid from the solitary lesion in 
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exa and in and around nerves. The granuloma fraction
was about 5%. Solid acid fast bacilli were seen in some of
the granulomas, singly and in small clusters of 3 to 5
bacilli; the BI of the granuloma was 2+. Based on the
smear results and histopathological report, the patient
was classified as borderline tuberculoid (BT) in the spec-
trum of Ridley and Jopling's classification [3].
Five months after commencement of MB MDT, the
patient developed a Type 1 or reversal reaction. This time,
there was palpable enlargement of a nerve and evidence of
nerve function impairment was observed. Again, we
assessed the patient for clinical, bacteriological and
immunological investigations. Clinically, the patient still
had the same single lesion. Bacteriologically, the routine
sites were still negative and the BI of the lesion was 1+.
The lateral flow for anti-PGL-I antibody was positive with
lesser intensity than the test done on his first visit indicat-
ing a lower bacterial load. The standard nerve function
measurements by VMT/ST were normal on both feet and
hands but some weakness was observed on the left foot
which concurs with enlargement of the left lateral pop-
liteal nerve.
Blood count was normal at this time and a whole blood
interferon gamma (IFN-γ) test was also performed to
measure the cell mediated immune responses towards
Mycobacterium tuberculosis purified protein derivative
(MTB PPD), M. leprae soluble antigen devoid of lipoarab-
inomannan (MLSA-LAM) and M. leprae cell wall antigen
(MLCwA), which were free of endotoxin and M. leprae
lipoarabinomannan, supplied by Professor Patrick J.
Brennan, Colorado State University, Fort Collins under
NIH contract NO1-AI-25469. These were tested by Quan-
tiFERON-CMI (Cellestis, Australia). IFN-γ production lev-
els were generated in response to stimulation with
Cellestis mitogen but no detectable levels of IFN-γ were
obtained against these antigens in our patient.
The reversal reaction was treated with 12 weeks of oral
prednisolone in a tapering dose and MDT was continued
unaltered during this period. Initially, the prednisolone
was prescribed at a dose of 40 mg per day for a 2-week
period, then decreased to 30 mg per day for 2 weeks, 20
mg per day for 2 weeks, 15 mg per day for 2 weeks, 10 mg
per day for another 2-week period and finally 5 mg per
day for 2 weeks.
Discussion
A solitary lesion with a high bacterial count is a rare occur-
rence and has been reported as an unusual presentation
[4-8]. The clinical presentation of our patient was consist-
ent with TT, but based on the evidence from histopathol-
ogy and bacteriology, the patient was shown to be
borderline tuberculoid (BT). Five months after the com-
mencement of MB MDT, he developed a reversal reaction,
which is due to delayed-type hypersensitivity and an
increase cell-mediated immunity to M. leprae antigens
resulting in localized tissue and nerve damage. Several
studies have reported higher levels of IFN-γ in BT leprosy
in Type 1 reaction; however, some studies have reported a
lack of demonstrable consistency in relation to cytokine
levels and reversal reactions [9].
Here, no IFN-γ was detected against the M. leprae fraction
antigens from this patient at this time point. He
responded well to oral prednisolone. Although, we could
not establish a clear correlation between the IFN-γ
response and the type of leprosy, using these antigens, a
significant difference was shown between healthy leprosy
contacts and unexposed endemic healthy controls in a
Nepali population in the production of IFN-γ [10].
Clinically, this case appeared as TT leprosy. But the skin
smear examination from the lesion showed an overall
moderately high BI at the lesion and the histopathological
examination confirmed that this was a lesion of BT lep-
rosy. This clinical and histopathological discrepancy has
been reported earlier [4,11,12]. This case emphasizes the
importance of skin smears and the histopathological
identification and classification of all patients with unu-
sual lesions. Without such information, this patient
would have been considered tuberculoid leprosy and
would have received the continuous treatment designed
for PB patients, which may not have been adequate.
Furthermore, the rapid lateral flow test for anti-Phenolic
glycolipid-I (PGL-I) antibody of M. leprae was highly pos-
itive at the beginning and moderately positive at the fol-
low-up. In one study, a lateral flow assay correctly
diagnosed 97.4% MB leprosy patients, with a specificity of
86.2% [13]. Detection of anti-PGL-I antibodies may thus
be an indicator of leprosy development and a useful com-
plementary tool in diagnosing MB leprosy in support of
clinical examination to direct the correct treatment regi-
men. Consequently, this evidence further supports the
view that this patient should have been treated by MB
MDT regimen from the beginning.
It is not always routinely possible to perform a his-
topathological examination, but skin smear from selective
sites, which is a relatively minor procedure, should always
be done in patients with one or a few skin patches to help
in differentiating MB from PB cases. This is all the more
important in a period when the disease is under control,
and patients reporting with early lesions and advanced
disease have become a rarity. This case is a rare case of
localized BT leprosy, whereas reports of localized leprom-
atous leprosy involving the extremities have been
reported earlier [12].Journal of Medical Case Reports 2009, 3:8 http://www.jmedicalcasereports.com/content/3/1/8
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The WHO has recommended that skin smears are not a
prerequisite for starting a patient on MDT. The clinical sys-
tem of classification which has been recommended for
the purpose of treatment includes the use of numbers of
skin lesions and nerves involved as the basis for classifying
patients into MB and PB. If in doubt, the WHO further rec-
ommends that the patient should be treated with MB reg-
imen [1].
This case further highlights the importance of performing
skin smears as a routine in all patients to differentiate MB
from PB disease. In the light of this case and previous
reports [4,5,14,15] of even lepromatous leprosy present-
ing as a single skin lesion, field workers, including both
medical and paramedical workers should carefully per-
form and interpret slit-skin smears from clinically diag-
nosed paucibacillary cases so that such unusual
presentations of the disease are treated appropriately and
not missed.
Conclusion
Importantly, the host immune response to M. leprae is
critical for controlling the infection, but is also responsi-
ble for the immunopathological damage that may
develop in nerves and specific organ sites. The presenta-
tion of a solitary lesion in multibacillary cases remains
rare and the onset of a reversal reaction with fast removal
of the bacterial load in the lesion further reinforces the
view that certain aspects of the host cell-mediated
response and pathophysiology of this important disease
are still not fully understood. It is important that patients
are classified correctly in the leprosy spectrum, so that
they may receive the most appropriate treatment.
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